MSC‑SCI
Spinal Cord Injury
Phase 1Active
Key Facts
About Advancells
India’s leading GMP‑compliant stem‑cell and exosome therapy provider for personalized regenerative medicine.
View full company profileTherapeutic Areas
Other Spinal Cord Injury Drugs
| Drug | Company | Phase |
|---|---|---|
| itNSCs | Stemedica Cell Technologies | Development |
| MAP4343 | Mapreg | Preclinical |
| Spinal Cord Injury Program | BioAxone Biosciences | Clinical |
| Undisclosed Scaffold Program | Innervace | Pre-clinical |
| Q-Cells | Q Therapeutics | Research |
| APOSEC | Aposcience | Pre-clinical |
| NG004 | Neurimmune | Phase 1 |
| Perineline™ | NeuroSolv Therapeutics | Phase 1 |
| Nogo-A Receptor Blocking Antibody | NovaGo Therapeutics | Phase 1b |
| Spinal Cord Injury (SCI) Neural Bridge | Matricelf | Preclinical |